{
    "medicine_id": "76c0dcb40bf5ea2e8dfb301f2f940f603c660d67",
    "platform_id": "DB11820",
    "metadata": {
        "name": "Lampit 30 mg 1 Tablet film coated",
        "composition": "30 mg 1 Nifurtimox",
        "clinical_particulars": {
            "therapeutic_indications": "Nifurtimox is indicated in pediatric patients under 18 weighing at least 2 5 kg Continued approval of this drug for this indication is dependent upon confirmatory clinical trial results L15361",
            "contraindications": {
                "disease": "There is limited information in the literature regarding overdose with nifurtimox Some symptoms of nifurtimox toxicity may include weight loss anorexia nausea vomiting vertigo headache nervous excitation insomnia convulsions drowsiness arthralgias myalgias disorientation abdominal pain mucosal edema and skin manifestations These symptoms are adverse effects of nifurtimox and are likely to be exaggerated with increased exposure A217891",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Nifurtimox exerts trypanosomal activity against Trypanosoma cruzi treating Chagas disease A216956 One study reports that nifurtimox and other benzofuran derivatives reduce parasite dehydrogenase activity A216941 Results of a recent phase III clinical trial L15381 have shown that a significant number of pediatric patients with acute or chronic Chagas disease treated with nifurtimox were immunoglobulin G IgG antibody negative and demonstrated at least a 20 decrease in optical density on two IgG antibody tests for T cruzi antigens L15361 L15506",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}